HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway

International Journal of Oncology

Volumn 49, Issue 6, 2016, Pages 2529-2537

  Wang, Hong ^a   Jia, Xiu Hong ^a   Chen, Jie Ru ^a   Yi, Ying Jie ^a   Wang, Jian Yong ^a   Li, You Jie ^a   Xie, Shu Yang ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

BCRP; Chronic myeloid leukaemia; HOXB4; MRP1; Multidrug resistance; P glycoprotein; Phosphoinositide 3 kinase

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HOMEODOMAIN PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; VINDESINE; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; HOXB4 PROTEIN, HUMAN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ARTICLE; BIOACCUMULATION; CELL COUNTING; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HOXB4 GENE; HUMAN; HUMAN CELL; IC50; K562 ADM CELL; K562 CELL LINE; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA CELL LINE; PRIORITY JOURNAL; REVERSE GENETICS; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LEUKEMIA, MYELOID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; CYTARABINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; VINDESINE;

EID: 84996508863     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3738     Document Type: Article

References (40)

1. Cao R, Wang Y and Huang N: Discovery of 2-acylaminothiophene-3-carboxamides as multitarget inhibitors for BCR-ABL kinase and microtubules. J Chem Inf Model 55: 2435-2442, 2015.
2. Mathisen MS, Kantarjian HM, Cortes J and Jabbour E: Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 96: 347-349, 2011.
3. Yandim MK, Ceylan C, Elmas E and Baran Y: A molecular and biophysical comparison of macromolecular changes in imatinibsensitive and imatinib-resistant K562 cells exposed to ponatinib. Tumour Biol 37: 2365-2378, 2016.
4. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412, 2009.
5. Sweet K and Pinilla-Ibarz J: Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. Crit Rev Oncol Hematol 103: 99-108, 2016.
6. Hochhaus A, Ernst T, Eigendorff E and La Rosée P: Causes of resistance and treatment choices of second-and third-line treatment in chronic myelogenous leukemia patients. Ann Hematol 94 (Suppl 2): S133-S140, 2015.
7. La Rosée P, Corbin AS, Stoffregen EP, Deininger MW and Druker BJ: Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62: 7149-7153, 2002.
8. Corrêa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L and Abdelhay E: Wnt/catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 12: 303, 2012.
9. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
10. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: From genomics to mechanism. Oncogene 22: 7468-7485, 2003.
11. Kalle AM, Sachchidanand S and Pallu R: Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res 34: 1132-1138, 2010.
12. Hoegg S and Meyer A: Hox clusters as models for vertebrate genome evolution. Trends Genet 21: 421-424, 2005.
13. Cillo C, Cantile M, Faiella A and Boncinelli E: Homeobox genes in normal and malignant cells. J Cell Physiol 188: 161-169, 2001.
14. Li N, Jia X, Wang J, Li Y and Xie S: Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of acute myeloid leukemia cells. Mol Med Rep 12: 6861-6866, 2015.
15. Yi YJ, Jia XH, Wang JY, Li YJ, Wang H and Xie SY: Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1. Int J Mol Med 37: 1405-1411, 2016.
16. Kavalerchik E, Goff D and Jamieson CH: Chronic myeloid leukemia stem cells. J Clin Oncol 26: 2911-2915, 2008.
17. Thorén LA, Liuba K, Bryder D, Nygren JM, Jensen CT, Qian H, Antonchuk J and Jacobsen SE: Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol 180: 2045-2053, 2008.
18. Zhang XB, Beard BC, Trobridge GD, Wood BL, Sale GE, Sud R, Humphries RK and Kiem HP: High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest 118: 1502-1510, 2008.
19. Bodey B, Bodey B Jr, Siegel SE and Kaiser HE: Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in breast carcinomas. Anticancer Res 20 (5A): 3281-3286, 2000.
20. Bodey B, Bodey B Jr, Gröger AM, Siegel SE and Kaiser HE: Immunocytochemical detection of homeobox B3, B4, and C6 gene product expression in lung carcinomas. Anticancer Res 20: 2711-2716, 2000.
21. Hwang SH, Kim KU, Kim JE, Kim HH, Lee MK, Lee CH, Lee SY, Oh T and An S: Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clin Chem Lab Med 49: 699-704, 2011.
22. Rodríguez-Rodero S, Fernández AF, Fernández-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, Urdinguio RG, Gonzalez-Marquez R, Suarez C, Fernández-Vega I, et al: DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 98: 2811-2821, 2013.
23. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, et al: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667, 2004.
24. Morgan R, Simpson G, Gray S, Gillett C, Tabi Z, Spicer J, Harrington KJ and Pandha HS: HOX transcription factors are potential targets and markers in malignant mesothelioma. BMC Cancer 16: 85, 2016.
25. Kelly Z, Moller-Levet C, McGrath S, Butler-Manuel S, Kavitha Madhuri T, Kierzek AM, Pandha H, Morgan R and Michael A: The prognostic significance of specific HOX gene expression patterns in ovarian cancer. Int J Cancer 139: 1608-1617, 2016.
26. Gordon-Keylock SA, Jackson M, Huang C, Samuel K, Axton RA, Oostendorp RA, Taylor H, Wilson J and Forrester LM: Induction of hematopoietic differentiation of mouse embryonic stem cells by an AGM-derived stromal cell line is not further enhanced by overexpression of HOXB4. Stem Cells Dev 19: 1687-1698, 2010.
27. Lehne G, Grasmo-Wendler UH, Berner JM, Meza-Zepeda LA, Adamsen BL, Flack A, Reiner A, Clausen OP, Hovig E and Myklebost O: Upregulation of stem cell genes in multidrug resistant K562 leukemia cells. Leuk Res 33: 1379-1385, 2009.
28. Sheng Z, Ma L, Sun JE, Zhu LJ and Green MR: BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 118: 2840-2848, 2011.
29. Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 30: 773-782, 2013.
30. Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 4: e923, 2013.
31. Mao Z, Zhou J, Luan J, Sheng W, Shen X and Dong X: Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 68: 179-183, 2014.
32. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, et al: Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-438, 2007.
33. Wang H, Jia XH, Chen JR, Wang JY and Li YJ: Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep 35: 3659-3668, 2016.
34. Chen JR, Jia XH, Wang H, Yi YJ, Wang JY and Li YJ: Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Int J Oncol 48: 2063-2070, 2016.
35. Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, Li WJ, Chen XP, Zhao XL, Chen FP and Zeng H: Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 336: 96-105, 2013.
36. Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1. PLoS One 9: e85113, 2014.
37. Zhang X, Dong W, Zhou H, Li H, Wang N, Miao X and Jia L: 2,8-sialyltransferase is involved in the development of multidrug resistance via PI3K/Akt pathway in human chronic myeloid leukemia. IUBMB Life 67: 77-87, 2015.
38. Cheng Z, Yang N, Liang W, Yan X, Li L and Pan L: Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells. Leuk Lymphoma 53: 1383-1389, 2012.
39. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T, Yamashita N, Oda M and Morishima T: Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59: 83-89, 2012.
40. Jung KA, Choi BH and Kwak MK: The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol 87: 465-476, 2015